-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Significant Drop in Short Interest
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Significant Drop in Short Interest
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) was the recipient of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 35,300 shares, a decrease of 27.5% from the October 15th total of 48,700 shares. Currently, 0.4% of the company's stock are short sold. Based on an average daily trading volume, of 31,100 shares, the days-to-cover ratio is currently 1.1 days.
Institutional Trading of Avalo Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Leo Brokerage LLC bought a new stake in shares of Avalo Therapeutics during the 1st quarter valued at $45,000. Assenagon Asset Management S.A. bought a new stake in Avalo Therapeutics during the third quarter valued at about $52,000. Renaissance Technologies LLC increased its position in Avalo Therapeutics by 819.1% in the first quarter. Renaissance Technologies LLC now owns 367,193 shares of the company's stock worth $266,000 after buying an additional 327,241 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Avalo Therapeutics by 23.8% in the second quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after buying an additional 124,769 shares during the period. Finally, Millennium Management LLC purchased a new position in shares of Avalo Therapeutics during the 2nd quarter valued at about $506,000.
Get Avalo Therapeutics alerts:Avalo Therapeutics Stock Performance
NASDAQ:AVTX traded down $0.30 on Friday, hitting $5.80. The stock had a trading volume of 32,230 shares, compared to its average volume of 24,928. Avalo Therapeutics has a 52-week low of $2.42 and a 52-week high of $27.96. The company has a current ratio of 1.07, a quick ratio of 0.97 and a debt-to-equity ratio of 5.23. The business's 50-day simple moving average is $4.90 and its two-hundred day simple moving average is $5.19.
Analyst Ratings Changes
Separately, Oppenheimer reduced their target price on Avalo Therapeutics from $17.00 to $10.00 in a report on Wednesday.Avalo Therapeutics Company Profile
(Get Rating)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Featured Articles
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) was the recipient of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 35,300 shares, a decrease of 27.5% from the October 15th total of 48,700 shares. Currently, 0.4% of the company's stock are short sold. Based on an average daily trading volume, of 31,100 shares, the days-to-cover ratio is currently 1.1 days.
阿瓦洛治疗公司(纳斯达克代码:AVTX-GET评级)是10月份空头股数使用量大幅下降的接受者。截至10月31日,空头股数共有3.53万股,比10月15日的4.87万股减少了27.5%。目前,该公司0.4%的股票被卖空。以日均成交量31,100股计算,目前天数与回补比率为1.1天。
Institutional Trading of Avalo Therapeutics
Avalo治疗公司的机构交易
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Leo Brokerage LLC bought a new stake in shares of Avalo Therapeutics during the 1st quarter valued at $45,000. Assenagon Asset Management S.A. bought a new stake in Avalo Therapeutics during the third quarter valued at about $52,000. Renaissance Technologies LLC increased its position in Avalo Therapeutics by 819.1% in the first quarter. Renaissance Technologies LLC now owns 367,193 shares of the company's stock worth $266,000 after buying an additional 327,241 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Avalo Therapeutics by 23.8% in the second quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after buying an additional 124,769 shares during the period. Finally, Millennium Management LLC purchased a new position in shares of Avalo Therapeutics during the 2nd quarter valued at about $506,000.
一些对冲基金和其他机构投资者最近增持或减持了该业务的股份。Leo Brokerage LLC在第一季度购买了Avalo治疗公司的新股份,价值4.5万美元。Assenagon Asset Management S.A.在第三季度购买了Avalo Treeutics的新股份,价值约5.2万美元。复兴技术公司在第一季度将其在阿瓦洛治疗公司的地位增加了819.1%。复兴科技有限责任公司现在持有该公司367,193股股票,价值266,000美元,上个季度又购买了327,241股。高盛股份有限公司在第二季度增持了阿瓦洛治疗公司的股份23.8%。高盛股份有限公司在此期间增持了124,769股,目前持有649,653股该公司股票,价值324,000美元。最后,Millennium Management LLC在第二季度购买了价值约506,000美元的Avalo治疗公司的新股票头寸。
Avalo Therapeutics Stock Performance
Avalo治疗公司股票表现
NASDAQ:AVTX traded down $0.30 on Friday, hitting $5.80. The stock had a trading volume of 32,230 shares, compared to its average volume of 24,928. Avalo Therapeutics has a 52-week low of $2.42 and a 52-week high of $27.96. The company has a current ratio of 1.07, a quick ratio of 0.97 and a debt-to-equity ratio of 5.23. The business's 50-day simple moving average is $4.90 and its two-hundred day simple moving average is $5.19.
纳斯达克:AVTX周五下跌0.3美元,触及5.8美元。该股成交量为32,230股,而其平均成交量为24,928股。Avalo Treateutics的52周低点为2.42美元,52周高位为27.96美元。该公司的流动比率为1.07,速动比率为0.97,债务权益比率为5.23。该业务的50日简单移动均线切入位为4.90美元,200日简单移动均线切入位为5.19美元。
Analyst Ratings Changes
分析师评级发生变化
Avalo Therapeutics Company Profile
Avalo治疗公司简介
(Get Rating)
(获取评级)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Avalo Treateutics,Inc.是一家临床阶段的精密药物公司,为免疫学、免疫肿瘤学和罕见遗传病方面未得到满足的临床需求的患者发现、开发和商业化靶向疗法。该公司开发了AVTX-002,这是一种完全人类抗光的单抗,正在进行第二阶段临床试验,用于治疗非嗜酸性哮喘以及炎症性肠道疾病,包括中到重度克罗恩病和溃疡性结肠炎;以及第三阶段临床试验,用于治疗新冠肺炎急性呼吸窘迫综合征。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- 免费获取StockNews.com关于Avalo治疗公司(AVTX)的研究报告
- MarketBeat:回顾中的一周11/7-11/11
- 油价是股市抛售尚未结束的一个令人信服的原因
- 中盘Neurocrine生物科学是井喷后的第三季度报告吗?
- 六面旗帜是一种你不想被困住的旅程
- Hanesbrand可能发出零售类股本周表现不佳的信号
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿瓦洛治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Avalo治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧